02552 Hua Medicine

Hua Medicine’s Leadership in Diabetes Treatment Recognized: CEO Dr. Li CHEN Awarded Prestigious C.C. Tan Life Science Industrialization Award

Hua Medicine’s Leadership in Diabetes Treatment Recognized: CEO Dr. Li CHEN Awarded Prestigious C.C. Tan Life Science Industrialization Award

SHANGHAI and SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , a pioneering biotechnology company, continues to lead the charge in diabetes treatment innovation. As global diabetes rates rise, Hua Medicine’s revolutionary approach is making significant strides, positioning China as a critical player in developing advanced healthcare solutions. In recognition of these efforts, Dr. Li CHEN, CEO and Founder of Hua Medicine, has been the prestigious C.C. Tan Life Science Industrialization Award.

Dr. Chen’s groundbreaking work, particularly in the development of dorzagliatin, a global first-in-class drug for Type 2 diabetes (T2D), has drawn global attention. Unlike conventional treatments, dorzagliatin regulates blood glucose levels by restoring the function of the body’s glucose sensor—the glucokinase—offering a pathway towards diabetes remission. This innovation represents a shift in how T2D can be managed and treated, demonstrating China’s capability to lead in global healthcare.

“As tensions around global trade and technology persist, it is crucial to acknowledge the progress being made by Chinese biotechnology firms like Hua Medicine,” said George Lin, Chief Strategy Officer at Hua Medicine. “Our innovations, particularly in the field of diabetes care, show that collaboration and acceptance of medical breakthroughs—regardless of their geographic origin—are essential to advancing global health outcomes.”

Hua Medicine’s efforts highlight the importance of strategic leadership in biotechnology and its potential to drive real-world health solutions. Mr. Lin emphasized the need for a balanced perspective in recognizing the innovations emerging from China, explaining that overlooking these advancements could set back global progress in treating chronic diseases.

Key Highlights of Hua Medicine’s Achievements Include:

• Dorzagliatin Development: A groundbreaking drug that aims to revolutionize the treatment of Type 2 diabetes by targeting the body’s glucose sensor.

• Global Recognition: Dr. CHEN’s latest award acknowledges his contributions to life sciences and leadership in advancing innovative treatments for diabetes.

• China’s Role in Biotech: As other parts of the world experience limited advancements in T2D treatments, China is making bold strides.

Dr. Chen’s recent award, the C.C. Tan Life Science Industrialization Award, is testament to Hua Medicine’s commitment to transforming healthcare solutions and improving outcomes globally.

For more information on Hua Medicine’s innovations and ongoing projects, please visit .

To set up an interview contact:

Alfred Romann

Managing Director, Bahati Ltd.

For Hua Medicine



EN
04/11/2024

Underlying

02552Hua Medicine

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hua Medicine

 PRESS RELEASE
Free
02552 HUA MEDICINE

Hua Medicine’s Leadership in Diabetes Treatment Recognized: CEO Dr. Li...

Hua Medicine’s Leadership in Diabetes Treatment Recognized: CEO Dr. Li CHEN Awarded Prestigious C.C. Tan Life Science Industrialization Award SHANGHAI and SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , a pioneering biotechnology company, continues to lead the charge in diabetes treatment innovation. As global diabetes rates rise, Hua Medicine’s revolutionary approach is making significant strides, positioning China as a critical player in developing advanced healthcare solutions. In recognition of these efforts, Dr. Li CHEN, CEO and Founder of Hua Medicine, has been the prestigious C...

November 4, 2024 1 EN
 PRESS RELEASE
Free
02552 HUA MEDICINE

华领医药成功完成Dorzagliatin单药治疗III期临床试验SEED...

华领医药成功完成Dorzagliatin单药治疗III期临床试验SEED研究（HMM0301） 中国，上海, June 18, 2020 (GLOBE NEWSWIRE) -- 华领医药（“公司”，香港联交所股份代号：2552.HK），一家针对全球糖尿病患者尚未满足的临床需求研发全球原创新药的生物技术公司，今天宣布了dorzagliatin的首个III期临床试验SEED（也称为HMM0301）的结果。Dorzagliatin是一款葡萄糖激酶启动剂（GKA）首创新药。52周试验在463名2型糖尿病患者中开展，旨在研究患者接受一天两次dorzagliatin 75mg用药治疗的疗效和安全性，前24周为随机双盲、安慰剂对照治疗，用以评估dorzagliatin的主要疗效终点和安全性，后28周为开放性药物治疗。 2019年11月，华领医药宣布SEED研究在前24周双盲治疗期达到主要疗效和安全性终点。基于核心资料分析，52周治疗保持了其疗效和安全性。在为期28周的开放药物治疗期间，最初接受安慰剂的患者（即安慰剂组）首次接受dorzagliatin治疗。图1说明了整个52周期间，两个治疗组的关键疗效结果[通过糖化血红蛋白(HbA1c)的下降评估]。 HbA1c下降水平：  24 weeks52 weeksp-value*Treatment Group (simple mean...

June 18, 2020 1 EN
 PRESS RELEASE
Free
02552 HUA MEDICINE

華領醫藥成功完成Dorzagliatin單藥治療III期臨床試驗SEED...

華領醫藥成功完成Dorzagliatin單藥治療III期臨床試驗SEED研究（HMM0301） 中國，上海, June 18, 2020 (GLOBE NEWSWIRE) -- 華領醫藥（“公司”，香港聯交所股份代號：2552.HK），一家針對全球糖尿病患者尚未滿足的臨床需求研發全球原創新藥的生物技術公司，今天宣佈了dorzagliatin的首個III期臨床試驗SEED（也稱為HMM0301）的結果。Dorzagliatin是一款葡萄糖激酶啟動劑（GKA）首創新藥。52周試驗在463名2型糖尿病患者中開展，旨在研究患者接受一天兩次dorzagliatin 75mg用藥治療的療效和安全性，前24周為隨機雙盲、安慰劑對照治療，用以評估dorzagliatin的主要療效終點和安全性，後28周為開放性藥物治療。 2019年11月，華領醫藥宣佈SEED研究在前24周雙盲治療期達到主要療效和安全性終點。基於核心資料分析，52周治療保持了其療效和安全性。在為期28周的開放藥物治療期間，最初接受安慰劑的患者（即安慰劑組）首次接受dorzagliatin治療。圖1說明了整個52周期間，兩個治療組的關鍵療效結果[通過糖化血紅蛋白(HbA1c)的下降評估]。 HbA1c下降水準：  24 weeks52 weeksp-value*Treatment Group (simple mean...

June 18, 2020 1 EN
 PRESS RELEASE
Free
02552 HUA MEDICINE

Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s P...

Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial SHANGHAI, China, June 18, 2020 (GLOBE NEWSWIRE) -- Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301), the first Phase III trial with dorzagliatin. Dorzagliatin is a first-in-class glucokinase activator. The 52-week trial investigated the efficacy and safety of 75mg BID dorzagliatin in 463 patients with Type 2 diabete...

June 18, 2020 1 EN
 PRESS RELEASE
Free
02552 HUA MEDICINE

Hua Medicine’s Dorzagliatin Demonstrates Improvements in β-Cell Fun...

Hua Medicine’s Dorzagliatin Demonstrates Improvements in β-Cell Function in Data Presented at the American Diabetes Association’s 80th Scientific Sessions SHANGHAI, China, June 15, 2020 (GLOBE NEWSWIRE) -- Hua Medicine (the “Company”, Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED, (also known as HMM0301). The following findings from the SEED study were presented in oral and symposium presentations at the American Di...

June 15, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch